Caffeine, chocolate, and adenosine antagonism in Parkinson's disease
Department of Neurology, University Hospital Dresden, Dresden 01307, Germany.
Correspondence to: Prof. Heinz Reichmann, Department of Neurology, University Hospital Dresden, Fetscherstraße 74, Dresden 01307, Germany. E-mail:
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. It is generally accepted that dopamine replacement therapy substantially improves motor symptoms; however, there is a worldwide tendency to include nutrients in treatment strategies. In the present review, caffeine and chocolate are discussed. Caffeine use seems to postpone the occurrence of PD in men, and perhaps also in women who do not take postmenopausal hormone replacement therapy. There are contradictory data concerning possible caffeine-induced improvements in PD symptoms. Given that the basic action of caffeine is the antagonism of adenosine receptors, adenosine antagonists may be a new option for treating PD patients. Furthermore, PD patients tend to have increased chocolate consumption; this may be causally related to ingredients such as phenylethylamine. Thus, nutrients such as caffeine and chocolate may play an important role in postponing and/or improving symptoms in PD.
Idiopathic Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is rapidly increasing in incidence. It is generally assumed that misfolded α-synuclein is the main constituent of Lewy bodies and is the major player in the etiopathogenesis of PD. Inflammation and oxidative stress also appear to have an important role in the death of dopaminergic neurons in this disease. Furthermore, PD seems to be a spreading disease[3,4] that affects not only the dopaminergic nigrostriatal system, but also many other parts of the brain and autonomic nervous system. The widespread appearance of misfolded α-synuclein causes the typical motor symptoms associated with PD - akinesia, rigidity, and tremor - and impairs the production and function of other neurotransmitters, thus leading to cognitive, psychiatric, autonomic, and other symptoms. Treatment of PD is mostly focused on repairing imbalances between the direct and indirect pathways (i.e., addressing and substituting the dopaminergic system by administering dopamine replacement therapy).
It would likely be well accepted if readily available and commonly used nutrients were able to improve the symptoms of PD or even postpone its onset. In light of this assumption, the following review focuses on our knowledge of caffeine and chocolate in the control of PD and also reviews the use of adenosine antagonists as a therapeutic approach.
FUNCTION OF CAFFEINE IN THE BRAIN
Caffeine (1,3,7-trimethylxanthine) is the most frequently used psychostimulant worldwide. It is a natural alkaloid and can be found in leaves and seeds (e.g., from coffee and cacao plants), from which it can be extracted. The stimulating effects of the cacao plant were recognized by the Maya culture, which led to its cultivation as early as 1000 BC. Caffeine can cross the blood-brain barrier and exerts its biological effects mainly via the antagonism of adenosine receptors. It inhibits lipid peroxidation and the formation of reactive oxygen species[6,7] and improves mitochondrial function. Caffeine is metabolized in the liver; its main metabolites are paraxanthine, theobromine, and theophylline. In common with its three metabolites, caffeine can cross all biological membranes and be excreted in urine. Because of its lipophilic structure, caffeine can also cross the blood-brain barrier and elicit its effects in the brain. Its blockade of the adenosine A1, A2A, and A3 receptors in glial cells, astrocytes, oligodendrocytes, and neurons modulates the release of dopamine, serotonin, acetylcholine, γ-aminobutyric acid (GABA), adrenaline, and noradrenaline in the nucleus accumbens, hippocampus and other brain regions, including the nigrostriatal system[5,9,10]. Caffeine also inhibits phosphodiesterases and causes calcium release from intracellular storage. Moreover, at moderate doses of 3-5 cups of coffee per day, it improves sleep, learning ability, cognition, and mobility. It thus seems clear that such a substance may have beneficial effects for patients with movement disorders, depression, migraines, or dementia[7,11-14]. Nonetheless, too high a dose of caffeine causes dysphoria, restlessness, nausea, and vomiting. The lethal dose for humans seems to be 100 cups of coffee or 10 g of caffeine per day.
CAFFEINE AND PD RISK
There is evidence from animal models that caffeine may reduce the risk of developing PD. The adenosine A2A receptor seems to play a key role in this protection in animal models of PD [e.g., the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model], and an A2A antagonist (KW6002; istradefylline) has been developed to treat patients with PD. The basic mechanism of the protective effect of caffeine/adenosine antagonists in animal models is not yet fully established, but may involve the prevention of blood-brain barrier disruption in addition to neuroprotective and antioxidative effects.
The first evidence of a possible neuroprotective effect of caffeine against PD came from the Honolulu Heart Program, in which more than 8000 participants were followed for 30 years or more. A high intake of caffeine (> 784 mg caffeine/day) reduced the risk of developing PD by fivefold. Paganini-Hill, who analyzed 395 patients from a retirement community in Southern California, obtained similar results. The author demonstrated that the risk of developing PD was significantly reduced in smokers, hypertensives, alcohol consumers, and coffee drinkers. The literature at that time pointed toward a tendency for men to benefit more from coffee than women with respect to PD; thus, Ascherio et al. prospectively investigated the interplay between estrogen and coffee consumption. They reported that caffeine reduces the risk of PD in women who do not use postmenopausal hormones, but increases the risk among hormone users. These findings suggest that women should avoid caffeine in combination with postmenopausal hormones. A study from Sweden of 415 same-sex twin pairs analyzed the influence of many lifestyle factors - such as smoking, alcohol, area of living, education, and caffeine consumption - on the risk of developing PD. Only smoking was found to have a positive effect. However, a major problem with this study was that, although coffee consumption led to a reduced risk of PD, the finding was not significant; this was likely because the controls also drank relatively high amounts of coffee. In contrast to the findings of
Caffeine consumption and risk of developing PD
|Ross et al., 2000||Honolulu Heart Programme||Caffeine reduced the risk of developing PD|
|Paganini-Hill et al., 2001||Retirement Community South California||Caffeine and smoking reduced the risk of developing PD|
|Ascherio et al., 2003||Caffeine reduces the risk of PD in men and in women who do not use postmenopausal hormones|
|Wirdefeldt et al., 2005||Swedish twin study||Nicotine but not caffeine reduced the risk of developing PD|
|Hu et al., 2007||Finnish study||Both men and women show a reduced risk of developing PD|
|Powers et al., 2008
Sääksjärvi et al., 2008
|If smoking and regular intake of nonsteroidal anti-inflammatory drugs are used in combination with caffeine, the risk of developing PD can be further reduced|
|Liu et al., 2012||Caffeine reduces the risk of developing PD|
|Qi et al., 2014||Caffeine reduces the risk of developing PD|
CAFFEINE AS A POSSIBLE TREATMENT FOR PATIENTS WITH PD
If caffeine is protective via adenosine receptors, it should also be determined whether it has beneficial effects in patients with established PD. In the Harvard Biomarkers Study, a longitudinal study involving 369 patients with PD - of whom 97 were de novo patients - and 197 healthy controls, high caffeine consumption resulted in a delayed need to start levodopa therapy. Patients consumed an average of 296 mg of caffeine per day, and those who consumed less caffeine had a higher prevalence of PD and more rapid disease progression. Higher espresso consumption also correlated with improved motor function [using the Unified Parkinson’s Disease Rating Scale (UPDRS)] and non-motor symptoms (using the Nonmotor-Symptoms Questionnaire). Prior to this, Altman et al. had reported that caffeine was associated with improved motor and non-motor symptoms in a smaller series of PD patients. Simon et al. evaluated the rate of disease progression when creatine, another possible neuroprotective substance, was administered in addition to coffee. This Phase III study involved 1741 PD patients; information about caffeine intake was available from 1549 participants. The influence of caffeine was analyzed using the UPDRS and the observation period was up to 5 years. There was no indication that caffeine had a beneficial effect on PD progression; on the contrary, caffeine combined with creatine was associated with a negative effect. In a randomized, controlled trial, patients with PD of 1-8 years of duration, Hoehn and Yahr stages I-III, and on stable symptomatic therapy were randomized to 200 mg caffeine or placebo capsules twice daily for 6-18 months. There was no improvement in either group (61 participants with placebo and 57 with caffeine) in the Movement Disorder Society UPDRS. There was a slight improvement in somnolence during the first 6 months as well as a slight increase in dyskinesia and worse cognitive testing scores in the caffeine group. Thus, the same research team that observed a positive effect of caffeine (with a decrease in UPDRS of 3.2 points) in a smaller, randomized trial of PD patients who did or did not receive caffeine found in this later study that caffeine was not associated with improvements in the condition of PD patients. The authors themselves stated that this difference may have been caused by different study populations. In the positive trial, patients were older and somnolent, had a longer disease duration, and were more often male. In favor of the negative study, it lasted for 6 months compared with 6 weeks in the positive study. In this context, it is surprising that the patients who received caffeine had poorer performance in the Montreal Cognitive Assessment Scale; this finding is contradictory to the normal stimulant effects of caffeine on alertness and cognitive function. Thus, it remains unclear whether caffeine improves motor or/and non-motor symptoms in PD. A summary of the studies is provided in Table 2.
Caffeine consumption and Parkinsonian symptoms
|Altman et al., 2011||Caffeine improved both motor and non-motor symptoms in PD patients|
|Bakshi et al., 2020||Harvard Biomarkers Study||Caffeine use resulted in later start with levodopa. High caffeine intake reduced the progression of the disease and improved motor function|
|Simon et al., 2015||Creatine phase III study||No improvement of motor symptoms by caffeine and worsening when creatine was added|
|Postuma et al., 2012||Improvement of UPDRS part III by 3,2 points|
|Postuma et al., 2017||Café-PD||No improvement of motor symptoms in patients with PD|
CAFFEINE AS A BIOMARKER FOR PD
Fujimaki et al. analyzed the levels of caffeine and 11 of its metabolites in the serum of 108 advanced-stage PD patients and compared them with the levels found in the serum of 31 healthy age- and sex-matched controls. Independent of disease stage, total caffeine intake, or disease severity, the levels of caffeine and nine metabolites - including theophylline, theobromine, and paraxanthine - were decreased in PD patients. Caffeine levels were, on average, 25% of those in healthy controls, theophylline 41%, theobromine 50%, and paraxanthine 42%. No genetic variants in CYP1A2 or CYP2E1, which encode cytochrome P450 enzymes that are primarily involved in metabolizing caffeine in humans, were identified compared with controls. Patients with dyskinesia had lower serum caffeine concentrations than those without dyskinesia. In addition, the authors were unable to detect genetic abnormalities in the gene encoding adenosine A2A receptors. Most of the patients and controls drank 1-3 cups of coffee per day and there was no difference between the two groups in the amount of coffee consumed. The findings of this study suggest that caffeine and its metabolites may be used as biomarkers for PD. A reasonable explanation for this observation may be that caffeine absorption is reduced in PD patients. Ohmichi et al. assessed the measurement of theophylline as a possible new biomarker in the serum of PD patients. Theophylline is a major metabolite of caffeine and is advantageous because it can easily be analyzed in most hospitals using standardized immunoassay kits. In addition, theophylline levels are less markedly affected by caffeine intake. The authors measured theophylline concentration in the serum of 31 patients with PD and 33 age-matched controls. On average, PD patients had 50% less theophylline in their serum than control individuals. The only weakness of this study is that it remains uncertain whether theophylline concentration is affected by coffee consumed before blood is drawn; further studies are therefore needed. The same group developed a specific enzyme-linked immunosorbent assay system for detecting caffeine in blood. In a series of 50 PD patients, 50 multiple system atrophy (MSA) patients, and 45 age-matched controls, serum caffeine concentration was significantly lower in PD patients (and, to a lesser extent, MSA patients) than in controls. In a first cohort of only 18 MSA patients, there was no significant difference between MSA patients and controls. Crotty et al. studied caffeine, among other analytes, in the cerebrospinal fluid and serum of 118 patients with a pathogenic mutation in the gene encoding leucine-rich repeat kinase 2 (LRRK2) and PD, 115 patients with a pathogenic mutation in LRRK2 but without PD symptoms, 70 idiopathic PD patients without LRKK2 mutations, and 68 controls. Plasma caffeine concentration was lower in patients with idiopathic or LRRK2-positive PD than in unaffected LRKK2-positive individuals, and was lower in LRRK2-positive PD than in idiopathic PD. It is intriguing that patients with PD and LRKK2 mutations had lower caffeine and metabolite levels than LRRK2-positive carriers without motor symptoms; this was true for both the cerebrospinal fluid and plasma. Notably, the LRRK2-positive patients with motor symptoms drank much less caffeine than those without symptoms. Thus, it may be that LRKK2-positive patients without PD symptoms drank more caffeine and were protected by attenuation of LRRK2-potentiated α-synuclein pathology. These observations encourage a long-term study on caffeine intake in LRRK2-positive carriers. Taken together, caffeine and its metabolites are promising biomarkers for PD.
ADENOSINE ANTAGONISM IN PD
Adenosine is an important neurotransmitter for neuronal maturation/development, sleep and arousal, cognition and memory, and control of respiration. A detailed description of the distribution, biochemistry, and functions of striatal adenosine A2A receptors can be found in Svenningsson et al.. In short, the main actions of caffeine in the brain are in adenosine receptor antagonism, intracellular Ca2+ release, and GABA receptor modulation. Adenosine receptors can be found in the striatum, globus pallidus, nucleus accumbens, and olfactory bulb. For PD, adenosine A2A receptors in the medium spiny neurons of the striatum are almost exclusively relevant. It thus makes sense to speculate that, similar to caffeine, drugs that antagonize adenosine receptors may be beneficial in PD. In this context, a positron emission tomography study by Ishibashi et al. is important; these authors demonstrated a significant occupancy of adenosine A2A receptors after participants drank a cup of coffee (equivalent to 100 mg caffeine). To date, there is only one licensed A2A receptor antagonist medication: istradefylline. This substance received approval in Japan in 2013 and in the USA in 2019; however, approval was recently denied by the European Medicines Agency. Istradefylline has been investigated in a large Phase II and Phase III clinical research program of about nine trials. On average, a gain of about 45-60 min of ON state and a decrease of about 45-60 min of OFF state have been identified. The most common side effect was dyskinesia, which was able to be overcome by adjusting levodopa dose.
CHOCOLATE AND PD
Chocolate, particularly dark chocolate, also contains caffeine. Specifically, 100 g of dark chocolate contains 43 mg of caffeine. Cacao-containing chocolate is highly valued worldwide for its taste and smell, as well as for its psychoactive stimulation. Approximately 20 years ago, I noticed that the bedside cupboard of a patient of mine - an in-patient who had traveled a long distance - was full of bars of chocolate. He told me that he had not been certain that we could provide him with his favorite chocolate, which improved his PD symptoms. On the basis of this observation, we performed a survey among our PD patients and revealed a significantly higher intake of chocolate in patients than that of their caregivers and partners; this preference for chocolate was independent of the presence or absence of depression. Furthermore, the consumption of other sweets was similar between PD patients and their caregivers and partners. Caffeine may be an underlying reason for this behavior, or perhaps energy production from glucose. The amine phenylethylamine, which can penetrate the blood-brain barrier, may also be responsible for our finding, or tryptophane, which is a precursor of serotonin. We favored the idea that phenylethylamine may be the reason for the high intake of chocolate and performed a study in which we compared phenylethylamine content in the blood of patients with PD who had eaten either dark or white chocolate. We tested the effects of 200 g of chocolate containing 80% cacao on the UPDRS motor score at 1 and 3 h in 26 subjects with moderate, non-fluctuating PD. The investigation was a mono-center, single-dose, investigator-blinded cross-over study using cacao-free white chocolate as the placebo. At 1 h after chocolate intake, mean UPDRS motor scores were mildly decreased compared with baseline in both treatment groups; however, only the dark chocolate results were significant [-1.3 (95% confidence interval [CI] 0.18-2.52, repeated measures analysis of variance F = 4.783, P = 0.013, Bonferroni P = 0.021)]. A 2 × 2 cross-over analysis revealed no significant differences between the two treatments [-0.54 ± 0.47 (95%CI: -1.50-0.42), P = 0.258]. Similar results were obtained 3 h after intake. Furthermore, β-phenylethylamine blood levels were unaltered. In summary, dark chocolate did not show significant improvements over white (cacao-free) chocolate in terms of PD motor function.
Caffeine and its metabolites play an important role in brain function. Caffeine may be neuroprotective against PD and slow the occurrence of this neurodegenerative disease. There are many more studies suggesting that coffee drinking lowers the risk of PD than those that suggest the opposite. However, the existing data on whether coffee, tea, or chocolate intake may improve symptoms in patients with PD are much more ambiguous. Given that caffeine acts mostly via adenosine receptors in many brain regions, further studies with new adenosine antagonists are needed.
The author thanks Dr. Sandra Jackson, Department of Neurology Dresden, for editing the manuscript. An excerpt of this work has been published in German: Reichmann H. Koffein, schokolade und adenosin A2A rezeptorantagonisten in der Behandlung des Parkinson syndroms. Fortschr Neurol Psychiatr 2022. DOIAuthor’s contribution
The author contributed solely to the article.Availability of data and materials
Not applicable.Financial support and sponsorship
Not applicable.Conflicts of interest
Prof. Reichmann H was invited by EISAI to give lectures on the function of the adenosine antagonist istradefylline.Ethical approval and consent to participate
Not applicable.Consent for publication
© The Author(s) 2022.
2. Shahmoradian SH, Lewis AJ, Genoud C, et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci 2019;22:1099-109.
3. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;396:67-72.
4. Borghammer P. The α-synuclein origin and connectome model (SOC model) of Parkinson’s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinsons Dis 2021;11:455-74.
5. Solinas M, Ferré S, You ZB, Karcz-kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 2002;22:6321-4.
6. Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1996;1282:63-70.
7. Schepici G, Silvestro S, Bramanti P, Mazzon E. Caffeine: an overview of its beneficial effects in experimental models and clinical trials of Parkinson’s disease. Int J Mol Sci 2020;21:4766.
8. Kolahdouzan M, Hamadeh MJ. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci Ther 2017;23:272-90.
9. Olopade FE, Femi-Akinlosotu OM, Adekanmbi AJ, Ighogboja OO, Shokunbi MT. Chronic caffeine ingestion improves motor function and increases dendritic length and arborization in the motor cortex, striatum, and cerebellum. J Caffeine Adenosine Res 2021;11:3-14.
10. Sheth S, Brito R, Mukherjea D, Rybak LP, Ramkumar V. Adenosine receptors: expression, function and regulation. Int J Mol Sci 2014;15:2024-52.
11. Fredholm BB, Svenningsson P. Why target brain adenosine receptors? Parkinsonism Relat Disord 2020;80 Suppl 1:S3-6.
12. Camandola S, Plick N, Mattson MP. Impact of coffee and cacao purine metabolites on neuroplasticity and neurodegenerative disease. Neurochem Res 2019;44:214-27.
13. Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease? Parkinsonism Relat Disord 2020;80 Suppl 1:S45-53.
15. Forth W, Adam O. Coffein: Umgang mit einem Genussmittel, das auch pharmakologische Wirkungen entfalten kann. Dtsch Arztebl 2001;98:2816.
16. Schwarzschild MA, Xu K, Oztas E, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease. Neurology 2003;61:S55-61.
17. Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson’s disease. J Neurol Sci 2006;248:9-15.
18. Chen X, Ghiribi O, Geiger JD. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer’s and Parkinson’s disease. J Alzheimers Dis 2010;20:S127-41.
19. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9.
20. Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001;20:118-24.
21. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 2003;60:790-5.
22. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol 2005;57:27-33.
23. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 2007;22:2242-8.
24. Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol 2008;167:553-60.
25. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord 2008;23:88-95.
26. Sääksjärvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Männistö S. Prospective study of coffee consumption and risk of Parkinson’s disease. Eur J Clin Nutr 2008;62:908-15.
27. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012;175:1200-7.
28. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int 2014;14:430-9.
29. Bakshi R, Macklin EA, Hung AY, et al. Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson’s disease in the harvard biomarkers study. J Parkinsons Dis 2020;10:505-10.
30. Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson’s disease: a pilot open-label, dose-escalation study. Mov Disord 2011;26:2427-31.
31. Simon DK, Wu C, Tilley BC, et al. Caffeine and progression of Parkinson disease: a deleterious interaction with creatine. Clin Neuropharmacol 2015;38:163-9.
32. Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): a randomized trial. Neurology 2017;89:1795-803.
33. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-8.
34. Fujimaki M, Saiki S, Li Y, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018;90:e404-11.
35. Ohmichi T, Kasai T, Kosaka T, et al. Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson’s disease. PLoS One 2018;13:e0201260.
36. Ohmichi T, Kasai T, Shinomoto M, et al. Quantification of blood caffeine levels in patients with Parkinson’s disease and multiple system atrophy by caffeine ELISA. Front Neurol 2020;11:580127.
37. Crotty GF, Maciuca R, Macklin EA, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: a metabolomic study. Neurology 2020;95:e3428-37.
38. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-96.
39. Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A receptor occupancy by caffeine after coffee intake in Parkinson’s disease. Mov Disord 2022;37:853-7.
40. Hauser RA, Hattori N, Fernandez H, et al. Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson’s disease: a pooled analysis of 8 phase 2b/3 trials. J Parkinsons Dis 2021;11:1663-75.
41. Wolz M, Kaminsky A, Löhle M, Koch R, Storch A, Reichmann H. Chocolate consumption is increased in Parkinson’s disease. Results from a self-questionnaire study. J Neurol 2009;256:488-92.
Cite This Article
Reichmann H. Caffeine, chocolate, and adenosine antagonism in Parkinson's disease. Ageing Neur Dis 2022;2:19. http://dx.doi.org/10.20517/and.2022.24
Reichmann H. Caffeine, chocolate, and adenosine antagonism in Parkinson's disease. Ageing and Neurodegenerative Diseases. 2022; 2(4): 19. http://dx.doi.org/10.20517/and.2022.24
Reichmann, Heinz. 2022. "Caffeine, chocolate, and adenosine antagonism in Parkinson's disease" Ageing and Neurodegenerative Diseases. 2, no.4: 19. http://dx.doi.org/10.20517/and.2022.24
Reichmann, H. Caffeine, chocolate, and adenosine antagonism in Parkinson's disease. Ageing. Neur. Dis. 2022, 2, 19. http://dx.doi.org/10.20517/and.2022.24
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at email@example.com.